Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Diffuse Astrocytoma
- Ganglioglioma
- Glioma
- Optic Pathway Glioma
- Pilocytic Astrocytoma
- Pilomyxoid Astrocytoma
- Pleomorphic Xanthoastrocytoma
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 6 years and 21 years
- Gender
- Both males and females
Description
All patients will receive HA proton therapy to 52.2 CGE or 54 CGE in 29 or 30 fractions, depending on tumor location. Patients will receive weekly magnetic resonance imaging (MRI) scans during the course of proton therapy to monitor changes in solid tumor or cystic volume. Such changes may prompt ad...
All patients will receive HA proton therapy to 52.2 CGE or 54 CGE in 29 or 30 fractions, depending on tumor location. Patients will receive weekly magnetic resonance imaging (MRI) scans during the course of proton therapy to monitor changes in solid tumor or cystic volume. Such changes may prompt adaptive therapy to improve coverage or minimize the RT dose to healthy structures. Neurocognitive outcomes, sensitive to measures of memory and learning, will be collected at baseline and continue to 5 years post therapy. Disease evaluation will be monitored with brain MRI.
Tracking Information
- NCT #
- NCT04065776
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Sahaja Acharya, MD St. Jude Children's Research Hospital
Get Well Soon